Statement on FIFA Decision Regarding Dr. Yves Jean-Bart

Port-au-Prince, Haiti, Nov. 20, 2020 (GLOBE NEWSWIRE) — In response to FIFA’s decision, Dr. Yves Jean-Bart’s spokesman Evan Nierman stated:


“FIFA’s decision is a travesty of justice and purely political move to avoid further controversy and bad press following a series of high-profile scandals. Unlike the Haitian judicial system that properly investigated and cleared Dr. Jean-Bart of any wrongdoing, FIFA failed to review actual evidence which is why Dr. Jean-Bart expects to be fully exonerated and reinstated after appealing to the Court of Arbitration for Sport.”

###



Evan Nierman
(954) 379-2115 (102)

Greene County Bancorp, Inc. Appoints Paul Slutzky as Chairman of the Board of Directors

CATSKILL, N.Y., Nov. 20, 2020 (GLOBE NEWSWIRE) — Greene County Bancorp, Inc. announced today that the Board of Directors has appointed Paul Slutzky to serve as Chairman of the Board.

Mr. Slutzky will be succeeding Martin Smith, in a planned retirement transition following Mr. Smith’s announced plan to retire from the Board. Mr. Smith had served on the Board of Directors since 1993, and was named Chairman in 2005.

Mr. Slutzky joined the Bank’s Board of Directors in 1992. Mr. Slutzky is a former co-owner of Hunter Mountain Ski Area and affiliated companies. He is also retired from I. & O. A. Slutzky, Inc., a general construction company. Mr. Slutzky brings over 40 years of valuable business and leadership skills, financial acumen, and many other qualities that are beneficial to the Board.

Commenting on the leadership transition, Donald Gibson, President & CEO stated; “I wish to praise Paul’s dynamic leadership and service. I believe the Bank is well positioned for the future and we look forward to Mr. Slutzky leading the Board of Directors. In addition I would like to thank Martin Smith for his unwavering dedication and commitment to our Bank and our community. I offer my congratulations for his well earned retirement.”

Paul Slutzky said, “I am thrilled to have this opportunity, particularly during this challenging time. As one of the last locally owned and operated community banks, we embrace the common goal of reinvigorating the economies of our local communities in the face of the coronavirus pandemic and its economic impact. I am honored by the confidence the Board of Directors has shown in me.”

Greene County Bancorp, Inc. is the parent company of the Bank of Greene County, a locally owned and operated community bank headquartered in Catskill, New York.

For Further Information Contact:
Martha Keeler
VP, Marketing Director
(518)943-2600
[email protected]



IIROC Trade Resumption – IP

Canada NewsWire

VANCOUVER, BC, Nov. 20, 2020 /CNW/ – Trading resumes in:

Company: ImagineAR Inc.

CSE Symbol: IP

All Issues: Yes

Resumption (ET): 9:30 AM

IIROC can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented to ensure a fair and orderly market. IIROC is the national self-regulatory organization which oversees all investment dealers and trading activity on debt 3and equity marketplaces in Canada.

SOURCE Investment Industry Regulatory Organization of Canada (IIROC)

Agilitee Limited Announces the Appointment of Verityhurst Capital to Advise on Capital Raising

JOHANNESBURG South Africa, Nov. 20, 2020 (GLOBE NEWSWIRE) — Agilitee Limited. (“Agilitee”), the electric vehicle manufacturer, today announced the plan of its capital raising exercise through the offering of 50,000,000 shares at a price of R20.00 per share. Of the offered shares, 10,000,000 shares are being offered as preferred shares that will have a dividend yield. Once the capital raising has been successfully completed, the Company will then start the process of listing the shares of the Company on a market that appreciates tech start-ups that operate in the EV industry such as Agilitee. The capital raising when successfully completed, will represent 5% of Agilitee’s outstanding share capital.

Agilitee’s shares are expected to begin trading on a favourable stock exchange in the third quarter of 2021. The offering is expected to close in June 2021, subject to customary closing conditions. Agilitee plans to float directly without an IPO as soon as the Capital Raising exercise is completed. The Company has also started to sell licenses for those who want to bring Agilitee’s electric scooters and motorcycles to their respective African Countries as main franchisees. Agilitee is selling the licenses for Agilitee South Africa, Agilitee Nigeria, Agilitee Zimbabwe to name just a few. The model is to sell these licenses and in turn the licensees would regional sub-licensees per state, region or province and sell the vehicles directly to the public. At no point will Agilitee sell the vehicles to the public as only the licensees will sell directly to the public, being supplied by Agilitee. There is one national license for each country.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these shares in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the CIPC regulations of such jurisdiction.

About
Agilitee

Agilitee manufactures and produces new electric vehicles, car charging facilities, and other products. Agilitee’s business spans over research, production and sales of electric vehicles. It is actively promoting the commercialization of new energy vehicles and connected cars and exploring the research and industrialization of intelligent technologies. www.agilitee.africa

About Verityhurst Capital

AN ADVISORY FIRM DEDICATED TO THE SUCCESS OF SMALL TO MIDDLE-MARKET COMPANIES IN AFRICA With Headquarters in Fourways, Johannesburg, Verityhurst Capital is an independent investment banking and advisory firm dedicated to the small to middle market companies in South Africa. Since the founding of Verityhurst Capital in 2019, the firm has provided honest and effective advice on mergers and acquisitions, private capital raising, financial restructuring, fairness opinions and valuations, and strategic advisory to the executive teams, boards of directors, and financial sponsors of public and private companies. Working with one of the most high-ranking Johannesburg Stock Exchange approved Sponsors and Designated Advisors, Verityhurst Capital can swiftly assist its clients in raising capital through listings on the Johannesburg Stock Exchange. www.verityhurstcapital.com

For more information

Email: [email protected] 

Website: www.verityhurstcapital.com 



Auris Medical Launches Website for AM-301-focused Subsidiary, Altamira Medica

Hamilton, Bermuda, November 20, 2020 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rhinology and allergy and CNS disorders, today announced the launch of a dedicated website for its affiliate Altamira Medica Ltd. The website, www.altamiramedica.com, offers quick and easy access to information about the Company’s development of AM-301, a drug-free nasal spray intended for self-protection against risks from exposure to airborne viruses and allergens.   

Altamira Medica Ltd. was set up in September 2020 as a subsidiary of Auris Medical Holding Ltd. to focus on and expedite the development of AM-301. Upon application into the nose, AM-301 forms a protective gel layer on the nasal mucosa. This thin film is designed to prevent the contact of airborne viruses and allergens with cells; in addition, the composition serves to “trap” such particles and help with their discharge. Together, this is designed to reduce the risk of upper respiratory infections and promote alleviation of allergic symptoms. The potential protective effects of AM-301 have been demonstrated to date in a SARS-CoV-2 assay. A short contact between AM-301’s key component and the virus suspension was sufficient to reduce the viral infectious load by up to 99%.

“We are proud to provide further updates on our AM-301 program through the new dedicated website“, commented Thomas Meyer, Auris Medical’s founder, Chairman and CEO. “Since the announcement of the program, we have received a lot of positive feedback on our approach of providing a simple, effective and affordable means for reducing risk when potentially exposed to airborne viruses or allergens. We are working hard to advance the AM-301 project quickly and aim to submit regulatory applications in 2021.” 

Altamira Medica’s website will be continuously updated with development updates, relevant background information and press releases.  

About Auris Medical

Auris Medical is a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rhinology and allergy and CNS disorders. The Company is focused on the development of intranasal betahistine for the treatment of vertigo (AM-125, in Phase 2) and for the prevention of antipsychotic-induced weight gain and somnolence (AM-201, post Phase 1b). With AM-301, the Company is developing a nasal spray for protection against airborne pathogens and allergens. In addition, Auris Medical has two Phase 3 programs under development: Sonsuvi® (AM-111) for acute inner ear hearing loss and Keyzilen® (AM-101) for acute inner ear tinnitus. The Company was founded in 2003 and is headquartered in Hamilton, Bermuda with its main operations in Basel, Switzerland. The shares of Auris Medical Holding Ltd. trade on the NASDAQ Capital Market under the symbol “EARS.”

Forward-looking Statements

This press release may contain statements that constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical facts and may include statements that address future operating, financial or business performance or Auris Medical’s strategies or expectations. In some cases, you can identify these statements by forward-looking words such as “may”, “might”, “will”, “should”, “expects”, “plans”, “anticipates”, “believes”, “estimates”, “predicts”, “projects”, “potential”, “outlook” or “continue”, or the negative of these terms or other comparable terminology. Forward-looking statements are based on management’s current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include, but are not limited to, Auris Medical’s need for and ability to raise substantial additional funding to continue the development of its product candidates, the ability to pursue strategic partnering and non-dilutive funding for its Phase 3 programs, the results of Auris Medical’s review of strategic options and the outcome of any action taken as a result of such review, the timing and conduct of clinical trials of Auris Medical’s product candidates, the clinical utility of Auris Medical’s product candidates, the timing or likelihood of regulatory filings and approvals, Auris Medical’s intellectual property position and Auris Medical’s financial position, including the impact of any future acquisitions, dispositions, partnerships, license transactions or changes to Auris Medical’s capital structure, including future securities offerings. These risks and uncertainties also include, but are not limited to, those described under the caption “Risk Factors” in Auris Medical’s Annual Report on Form 20-F for the year ended December 31, 2019, and in Auris Medical’s other filings with the SEC, which are available free of charge on the Securities Exchange Commission’s website at: www.sec.gov. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated. All forward-looking statements and all subsequent written and oral forward-looking statements attributable to Auris Medical or to persons acting on behalf of Auris Medical are expressly qualified in their entirety by reference to these risks and uncertainties. You should not place undue reliance on forward-looking statements. Forward-looking statements speak only as of the date they are made, and Auris Medical does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law.

Investor contact:

Joseph Green
Edison Advisor for Auris Medical
646-653-7030
[email protected]

or

[email protected]  



IIROC Trading Resumption – QNC

Canada NewsWire

VANCOUVER, BC, Nov. 20, 2020 /CNW/ – Trading resumes in:

Company: Quantum Numbers Corp.

TSX-Venture Symbol: QNC

All Issues: Yes

Resumption (ET): 9:30 AM

IIROC can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented to ensure a fair and orderly market. IIROC is the national self-regulatory organization which oversees all investment dealers and trading activity on debt and equity marketplaces in Canada.

SOURCE Investment Industry Regulatory Organization of Canada (IIROC) – Halts/Resumptions

Aphria Inc. Files Amended and Restated Base Shelf Prospectus

PR Newswire

Increases Shelf Prospectus by USD $50 Million to Accommodate Equity to be Issued as Part of Consideration for the Acquisition of SweetWater

LEAMINGTON, ON, Nov. 20, 2020 /PRNewswire/ – Aphria Inc. (“Aphria” or the “Company“) (TSX: APHA) (NASDAQ: APHA), a leading global cannabis company inspiring and empowering the worldwide community to live their very best life, today announced that it has filed an amended and restated short form base shelf prospectus (the “Shelf Prospectus“) with the securities regulators in each of the provinces and territories  of Canada, and a corresponding shelf registration statement on Form F–10 (the “Registration Statement“) with the United States Securities and Exchange Commission (the “SEC“).  This Shelf Prospectus, among other things, increases the amount available under the Company’s original base shelf prospectus by USD $50 million, which will be used to qualify and register the resale of the common shares of the Company issued as partial consideration pursuant to the terms of the previously disclosed agreement  to acquire SW Brewing Company, LLC (“SweetWater”).

The Shelf Prospectus and Registration Statement allows the Company and/or selling security holders to make offerings of common shares, debt securities, subscription receipts, convertible securities, rights, units, warrants or any combination thereof of up to an aggregate of USD $550 million (or the equivalent thereof in other currencies based on the applicable exchange rate at the time of any offering) during the 25-month period that the Shelf Prospectus is effective.

The entire USD $500 million allocated under the original prospectus and registration statement has been used for previous issuances or reserved for the issuance of shares underlying warrants and the resale of the convertible notes and/or the common shares issuable upon conversion of the notes by the holders of such securities.   Should the Company and/or selling security holders decide to offer securities during this period, the specific terms, including the use of proceeds from any offering, will be set forth in a related prospectus supplement to the Shelf Prospectus, which will be filed with the applicable Canadian securities regulatory authorities and the SEC.

A copy of the Shelf Prospectus can be found on SEDAR at www.sedar.com and a copy of the Registration Statement can be found on EDGAR at www.sec.gov.

The Registration Statement has been filed with the SEC but has not yet become effective. No securities of the Company may be sold nor may offers to buy such securities be accepted prior to the time the Registration Statement becomes effective. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which an offer, solicitation or sale would be unlawful prior to registration or qualifications under the securities laws of any such jurisdiction.

We Have A Good Thing Growing

About Aphria Inc.
Aphria Inc. is a leading global cannabis company inspiring and empowering the worldwide community to live their very best life. Headquartered in Leamington, Ontario – the greenhouse capital of Canada – Aphria Inc. has been setting the standard for the low-cost production of high-quality cannabis at scale, grown in the most natural conditions possible. Focusing on untapped opportunities and backed by the latest technologies, Aphria Inc. is committed to bringing breakthrough innovation to the global cannabis market. The Company’s portfolio of brands is grounded in expertly researched consumer insights designed to meet the needs of every consumer segment. Rooted in our founders’ multi-generational expertise in commercial agriculture, Aphria Inc. drives sustainable long-term shareholder value through a diversified approach to innovation, strategic partnerships, and global expansion.

For more information, visit: aphriainc.com

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS: Certain information in this news release constitutes forward-looking statements under applicable securities laws and are expressly qualified by this cautionary statement. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward looking statements are often identified by terms such as “may”, “should”, “anticipate”, “expect”, “potential”, “believe”, “intend” or the negative of these terms and similar expressions. Forward-looking statements are based on the opinions, estimates and perception of trends of management and its beliefs with respect to future events, as at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. Factors that may cause such differences include, but are not limited to, risks associated with COVID-19 nationally and globally which could have a material adverse impact on Aphria’s business, operations and financial results, including disruptions in cultivation and processing, supply chains and sales channels, as well as a deterioration of general economic conditions including national and/or global recessions and the response of governments to the COVID-19 pandemic in respect of the operation of retail stores or pharmacies (as applicable); the ability of the Company to complete the acquisition of SweetWater; general economic conditions; adverse industry events; marketing costs; loss of markets; future legislative and regulatory developments involving cannabis or otherwise affecting Aphria’s business or its consumers generally; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favorable terms; the cannabis industry in Canada generally; income tax and regulatory matters, including delays in the issuance of licenses; the sale and distribution of vapes; the ability of Aphria to meet its liquidity requirements to fund ongoing operations; the ability of Aphria to implement its business strategies; competition; crop failure; safety of derivative cannabis products; currency and interest rate fluctuations. 

Readers are cautioned that the foregoing list is not exhaustive and should carefully review the various risks and uncertainties identified in the Company’s filings on SEDAR and EDGAR. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions, or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities laws.  Neither TSX nor its Regulation Services Provider (as that term is defined in the policies of Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/aphria-inc-files-amended-and-restated-base-shelf-prospectus-301178095.html

SOURCE Aphria Inc.

Tantech Announces Pricing of $10 Million Registered Direct Offering

PR Newswire

LISHUI, China, Nov. 20, 2020 /PRNewswire/ — Tantech Holdings Ltd (NASDAQ: TANH) (“Tantech” or the “Company”), a clean energy company based in China, today announced that it has entered into a securities purchase agreement with institutional investors to purchase approximately $10 million of its common shares and registered warrants to purchase common shares in a registered direct offering as well as unregistered warrants to purchase common shares in a concurrent private placement. The Company plans to use the net proceeds from the offering for working capital and general business purposes.

Under the terms of the securities purchase agreement, Tantech has agreed to sell to the institutional investors a total of 6,060,608 common shares (the “Purchased Shares”) priced at $1.65 per share, with registered warrants for 2,754,820 common shares. In the private placement, which will be consummated concurrently with the registered direct offering, Tantech has agreed to issue unregistered warrants to purchase up to an aggregate of 3,305,788 common shares. The Company has agreed to register the unregistered warrants in a separate registration statement within 60 days of the offering’s closing. The registered warrants and the unregistered warrants will be immediately exercisable, will expire 5 years from the date of issuance and will have an exercise price of $1.81 per share. The Company is also issuing to Univest Securities, LLC, which is acting as the sole placement agent for the offering, warrants for 363,637 common shares, with an exercise price of $1.815, under the private placement. The placement agent’s warrants are exercisable at any time during the period commencing 6 months after the closing date of the offering through the third anniversary of issuance.

The gross proceeds to the Company from the registered direct offering and concurrent private placement are estimated to be approximately $10 million before deducting the placement agent’s fees and other standard offering expenses. The offering is expected to close on or about November 24, 2020, subject to the satisfaction of customary closing conditions.

The Placement Agent has required that the officers, directors and 10% shareholders of the Company enter into lock-up agreements pursuant to which these persons agree that, without the prior consent of the Placement Agent, they will not, for a period of 90 days following the closing of the offering, subject to certain exceptions, offer, sell or otherwise dispose of or transfer any securities of the Company owned by them as of the date of the closing of the offering or acquired during the lock-up period.

The Purchased Shares, the registered warrants and the common shares underlying the registered warrants are being offered pursuant to a shelf registration statement on Form F-3 (File No. 333-248197) previously filed and declared effective by the Securities and Exchange Commission (SEC) on August 31, 2020 (the “Shelf Registration Statement”). The offering of the Purchased Shares, the registered warrants and the common shares underlying the registered warrants will be made only by means of a prospectus supplement that forms a part of the registration statement.

Univest Securities, LLC is acting as the exclusive placement agent for this offering.

This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor will there be any sales of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. A prospectus supplement relating to the Purchased Shares, the registered warrants and the common shares underlying the registered warrants will be filed by Tantech with the SEC. When available, copies of the prospectus supplement relating to the registered direct offering, together with the accompanying prospectus, can be obtained at the SEC’s website at www.sec.gov.

About Tantech Holdings Ltd.

Established in 2001 and headquartered in Lishui City, Zhejiang Province, China, Tantech, together with its subsidiaries, is now, in addition to be a developer and manufacturer of bamboo-based charcoal, an innovative leader in the design, manufacture and distribution of electric vehicles. The Company has also invested in mining business in 2018 and 2019.

For more information please visit: http://ir.tantech.cn.


Forward-Looking Statements

This news release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, economic conditions, the impact of competition and pricing, government regulations, and other risks contained in reports filed by the company with the Securities and Exchange Commission. All such forward-looking statements, whether written or oral, and whether made by or on behalf of the Company, are expressly qualified by this cautionary statement and any other cautionary statements which may accompany the forward-looking statements. In addition, the Company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.

Cision View original content:http://www.prnewswire.com/news-releases/tantech-announces-pricing-of-10-million-registered-direct-offering-301178089.html

SOURCE Tantech Holdings Ltd.

Timber Pharmaceuticals Signs Waiver Agreement with Warrant Holders

WOODCLIFF LAKE, NJ, Nov. 20, 2020 (GLOBE NEWSWIRE) — NewMediaWire — Timber Pharmaceuticals, Inc. (“Timber” or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announced that it has signed waiver agreements with certain of its existing institutional investors. 

Effective as of November 19, 2020 (the “Effective Date”), Timber entered into waiver agreements (the “Waiver Agreements”) with each of the holders of its series A and series B warrants in which all the parties agreed to waive certain rights and amend certain provisions of the warrants and associated securities purchase agreement.

Pursuant to the Waiver Agreements, the holders agreed to (i) waive certain provisions in the warrants in order to allow for one immediate and final reset of the number of shares of common stock underlying the warrants and the exercise price of the series A warrants using the formula provided in the warrants*, and (ii) permanently waive the provisions providing for future resets of the number of shares of common stock underlying the warrants and the exercise price of the series A warrants (other than certain anti-dilution protection provisions in the series A warrants). As a result of the foregoing, (A) the exercise price of the series A warrants was set at $1.16 per share (the “Series A Exercise Price”), (B) the number of shares underlying all of the series A warrants was set at 20,178,214 and (C) the number of shares underlying all of the Series B Warrants was set at 22,766,776.

“We are pleased to sign these agreements which we believe will put Timber on firmer footing to reach its strategic goals,” said John Koconis, Chief Executive Officer of Timber Pharma.

* For additional details of the agreement, see the Company’s Form 8-K filed with the Securities and Exchange Commission on November 20, 2020. 

About Timber Pharmaceuticals, Inc.

Timber Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases. The Company’s investigational therapies have proven mechanisms-of-action backed by decades of clinical experience and well-established CMC (chemistry, manufacturing and control) and safety profiles. The Company is initially focused on developing non-systemic treatments for rare dermatologic diseases including congenital ichthyosis (CI), facial angiofibromas (FAs) in tuberous sclerosis complex (TSC), and localized scleroderma. For more information, visit www.timberpharma.com.

Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company’s product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions.

These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential, “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company’s Form 10-Q filed on August 18, 2020 and its other filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

For more information, contact:

Timber Pharmaceuticals, Inc. 
John Koconis 
Chief Executive Officer
[email protected]

Investor Relations:
Stephanie Prince
PCG Advisory
(646) 762-4518
[email protected]

Media Relations: 
Adam Daley
Berry & Company Public Relations 
(212) 253-8881
[email protected]



StitcherAds Helps Retailers Promote Products from Black-Owned Businesses During Facebook’s #BuyBlack Friday Campaign

NEW YORK, Nov. 20, 2020 (GLOBE NEWSWIRE) — StitcherAds, the leading platform for ad solutions and shopping experiences that drive incremental sales on Facebook, Instagram, Pinterest, and Snapchat, today announced that it’s lending its overlay technology to retailers for free to help them highlight products from Black-owned brands in ads on Facebook and Instagram in support of Facebook’s #BuyBlack Friday campaign.

Facebook recently announced a ‘Season of Support,’ offering three months of support, resources, education, and thought leadership to support small businesses through this challenging holiday season. As part of Season of Support, Facebook launched the #BuyBlack Friday campaign in the US — redistributing the energy of the biggest physical retail day of the year to celebrate and support Black businesses and their communities. From October 30 – November 27, every Friday during Facebook’s Season of Support will spotlight Black businesses, celebrate Black culture and inspire consumers to #BuyBlack.

To help major retailers support the #BuyBlack Friday initiative across Facebook’s properties, StitcherAds is lending its overlay technology to retailers for free. With that, StitcherAds is making it easier for retailers to automate the promotion of products from Black-owned businesses across ads on Facebook and Instagram. Product feeds for top retailers can feature millions of products from thousands of brands. StitcherAds’ #BuyBlack offering will automatically help to highlight the Black-owned businesses from those product feeds.

StitcherAds’ technology makes it possible for retailers to uncover and categorize offers, products and deals across categories – from beauty and fashion to home decor and everything in between. With this capability, retailers can automatically showcase products from Black-owned businesses during Facebook’s #BuyBlack Friday campaign.

“Facebook is committed to supporting and celebrating Black-owned businesses and their communities in the lead up to what has traditionally been the biggest retail day of the year,” said Alvin Bowles, VP of Business Engineering & Partnership Solutions at Facebook. “We are excited about how StitcherAds is able to support our #BuyBlack Friday initiative in helping retailers showcase products from Black-owned businesses across their campaigns on Facebook and Instagram.”

“This holiday season will be challenging for many small businesses, with more people shopping online than ever before,” said Declan Kennedy, CEO and Co-Founder, StitcherAds. “Facebook’s determination to help small businesses thrive is commendable. And, this year’s focus on celebrating Black-owned businesses and their communities is exquisite. We are honored to be able to play a role in helping to drive Facebook’s initiative forward.”

StitcherAds technology helps advertisers to scale full-funnel performance marketing campaigns on Facebook, Instagram, Pinterest, and Snapchat. The company has empowered some of the largest advertisers worldwide using data-fueled automation to drive sales online and in-store.

Learn more about StitcherAds here: https://stitcherads.com/

About
StitcherAds

Founded in 2009, StitcherAds is a Facebook Marketing Partner helping advertisers and agencies scale full-funnel performance marketing campaigns on Facebook & Instagram. Since conception, StitcherAds has empowered some of Facebook’s largest advertisers for eCommerce, retail, travel, and real estate businesses worldwide, using data-fueled automation to increase the revenue impact of their ad spend. The company works on a hybrid service model, onboarding clients from fully managed service to self-serve to ensure long-term success with their software. As the first partner to launch dynamic ads and dynamic ads for travel on Facebook, StitcherAds has been a leader in both speed and achievement in direct response innovation. For more information about StitcherAds, please go to www.stitcherads.com.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/60b22d62-aa18-4d5b-a3f9-c8efff00288f



Chris Harihar
[email protected]